Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group Study

Journal of Clinical Oncology

Volumn 23, Issue 13, 2005, Pages 2988-2995

  Evans, T R Jeffry ^a   Yellowlees, Ann ^b   Foster, Elizabeth ^b   Earl, Helena ^b   Cameron, David A ^b   Hutcheon, Andrew W ^b   Coleman, Robert E ^b   Perren, Timothy ^b   Gallagher, Christopher J ^b   Quigley, Mary ^b   Crown, John ^b   Jones, Alison L ^b   Highley, Martin ^b   Leonard, Robert C F ^b   Mansi, Janine L ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; AC PROTOCOL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN TOXICITY; STOMATITIS; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING; ADJUVANT THERAPY; BREAST TUMOR; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; TAXOIDS; TREATMENT OUTCOME;

EID: 21144439271     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.156     Document Type: Article

References (53)

1. Bonadonna G, Valagussa P: Primary chemotherapy in operable breast cancer. Semin Oncol 23:464-476, 1996
2. Bonadonna G, Valagussa P, Zucali R, et al: Primary chemotherapy in surgically respectable breast cancer. CA Cancer J Clin 45:227-243, 1995
3. Ellis PA, Smith IE: Primary chemotherapy for early breast cancer. Cancer Treat Rev 22:437-450, 1996
4. Mansi JL, Smith IE, Walsh G, et al: Primary medical therapy for operable breast cancer. Eur J Cancer Clin Oncol 25:1623-1627, 1989
5. Jacquillat C, Weil M, Baillet F, et al: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 66:119-128, 1990
6. G. Mauriac L, Durand M, Avril A, et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Ann Oncol 2:347-354, 1991
7. Anderson EDC, Forrest APM, Hawkins RA, et al: Primary systemic therapy for operable breast cancer. Br J Cancer 63:561-566, 1991
8. Belembaogo E, Feillet V, Chollet P, et al: Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A:896-900, 1992
9. Calais G, Berger C, Descamps P, et al: Conservative treatment feasibility with induction chemotherapy, surgery and radiotherapy for patients with breast carcinoma larger than 3cm. Cancer 74:1283-1288, 1994
10. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery. Preliminary results of a randomised trial. Eur J Cancer 30A:645-652, 1994
11. Semiglazov VF, Topuzov EE, Bavli JL, et al: Primary (neoadjuvant) chemotherapy and radiotherapy compared with radiotherapy alone in stage IIB/IIIA breast cancer. Ann Oncol 5:591-595, 1994
12. Powles TJ, Hickish TF, Makris A, et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552, 1995
13. Smith IE, Walsh G, Jones A, et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13:424-429, 1995
14. Bonadonna G, Valagussa P, Brambilla C, et al: Primary chemotherapy in operable breast cancer: 8-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998
15. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
16. Van der Hage JA, Van de Velde CJH, Julien J-P, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001
17. Shannon C, Smith IE: Is there still a role of neoadjuvant therapy in breast cancer? Crit Rev Oncol/Hematol 45:77-90, 2003
18. Cunningham JD, Weiss SE, Ahmed S, et al: The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer. Cancer Invest 16:80-86, 1998
19. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
20. Coconi G, di Blasio B, Bisagni G, et al: Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. Am J Clin Oncol 13:226-232, 1990
21. Schwartz GF, Cantor RI, Biermann WA: Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast. Arch Surg 122:1430-1434, 1987
22. Pelissier P, Delalogue S, Mathieu M-C, et al: Intensified anthracyline does not improve clinical and pathological responses to neoadjuvant FEC for operable breast cancer: Results of a multicenter randomised trial. Proc Am Soc Clin Oncol 21:649, 2002 (abstr 254)
23. Ravdin PM, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
24. demons M, Leahy M, Valle J, et al: Review of recent trials of chemotherapy for advanced breast cancer: The Taxanes. Eur J Cancer 33:2183-2193, 1997
25. Piccart MJ, Awada A, Hamilton A: Integration of new therapies into the management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular makers, and newly developed biologic therapies in late clinical development. Perry MC (ed): Am Soc Clin Oncol Ed Book 526-539, 1999
26. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
27. Nabholtz JM, Crown J: Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: Preliminary results. Semin Oncol 25:4-9, 1998
28. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:422-428, 1996
29. 2 as first-line chemotherapy for patients with advanced breast cancer. Br J Cancer 74:650-656, 1996
30. ten Bokkel Huinik WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC-ECTG. Ann Oncol 5:527-532, 1994
31. Hudis CA, Seidman AD, Crown JPA, et al: Phase II pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
32. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Co-Operative Group of the EORTC. Ann Oncol 7:165-171, 1996
33. Nabholtz JM, Riva A: Taxane/anthracycline combinations: Setting a new standard in breast cancer? Oncologist 6:5-12, 2001 (suppl 3)
34. Misset JL, Dieras V, Gruia G, et al: Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10:553-560, 1999
35. Palmeri S, Leonardi V, Tamburo de Bella M, et al: Doxorubicin-docetaxel sequential schedule: Results of front-line treatment in advanced breast cancer. Oncology 63:205-212, 2002
36. Aihara T, Takatsuka Y, Itoh K, et al: Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer. Oncology 64:124-130, 2003
37. Nabholtz JM, Falkson C, Campos D, et al: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975, 2003
38. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997
39. Smith IE, A'Hern RP, Coombes GA, et al: A novel continuous infusional 5-fluouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 15:751-758, 2004
40. Miller AB, Hoogrstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
41. Jackisch C, von Minckwitz G, Eidtmann H, et al: Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: Second interim analysis. Clin Breast Cancer 3:276-280, 2002
42. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003
43. Smith IE, Jones AL, O'Brien MER, et al: Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29a: 1796-1799, 1993
44. Hortobagyi GN, Ames GR, Buzdar FC, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62:2507-2516, 1988
45. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
46. Von Minckwitz G, Costa SD, Raab G, et al: Dose dense doxorubicin, docetaxel, and granulocyte-stimulating factor support with or without taxomifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase Mb study. J Clin Oncol 19:3506-3515, 2001
47. Buzdar AU, Singletary SE, Theriault RL, et al: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417, 1999
48. Miller KD, McCaskill-Stevens W, Sisk J, et al: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037, 1999
49. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466, 2002
50. Kaufmann M, von Minckwitz G, Smith R, et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Reviews and recommendations. J Clin Oncol 21:2600-2608, 2003
51. Bonadonna G, Valagussa P, Brambilla C, et al: Preoperative chemotherapy in operable breast cancer. Lancet 341:1485, 1993
52. Pierga JY, Moiret E, Dieras V, et al: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83:1480-1487, 2000
53. Ganem G, Tubiana-Hulin M, Fumoleau P, et al: Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:1623-1628, 2003